US equities |
NVDA $239.25 ▲+0.14% MU $1,047.66 ▼-1.53% SPCX $172.84 ▲+1.03% MRVL $286.23 ▲+5.52% AMD $651.87 ▲+3.18% INTC $113.34 ▼-2.45% AVGO $377.55 ▲+4.15% SNDK $1,656.19 ▼-2.81%
FinancialContent

Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

13.57 -0.37 (-2.62%)
Delayed Quote Updated: 3:38 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crescent Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at September Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at June Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at May Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving on Friday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at March Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >